Mostrar el registro sencillo del ítem

dc.contributor.authorMartinón Torres, Federico 
dc.contributor.authorNolan, T.
dc.contributor.authorToneatto, D.
dc.contributor.authorBanzhoff, A.
dc.date.accessioned2021-10-14T07:33:40Z
dc.date.available2021-10-14T07:33:40Z
dc.date.issued2019
dc.identifier.issn2164-5515
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31246520
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930112/pdf/khvi-15-12-1627159.pdf
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15502
dc.description.abstractThe multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody persistence and booster following primary 4CMenB vaccination of infants, children, adolescents, and young adults. Putative seroprotective hSBA titers for >/=1 vaccine antigen were maintained by 76-100% of children 24-36 months after priming during infancy and in 84-100% after priming in the second year of life. hSBA levels were higher in vaccinees at 4 and 7.5 years following priming during adolescence than in vaccine-naive individuals of a similar age. Antibodies persisted at higher levels to NHBA and NadA than to PorA or fHbp. Booster vaccination induced robust anamnestic responses, demonstrating effective priming by 4CMenB across age-groups. These data can inform decision-making to optimize vaccination strategies.
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePersistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
dc.typeArtigoes
dc.authorsophosMartinón Torres, Federico
dc.identifier.doi10.1080/21645515.2019.1627159
dc.identifier.pmid31246520
dc.identifier.sophos30862
dc.issue.number12
dc.journal.titleHuman Vaccines & Immunotherapeutics 
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatría
dc.page.initial2940es
dc.page.final2951es
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo de Revisión
dc.volume.number15


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional